Dongsung Pharmaceutical Audit Report Corrected: Opinion Downgraded to Qualified, Internal Control Disclaimer

Audit report corrected: Financial statement opinion changed from unqualified to qualified; internal control opinion changed from unqualified to disclaimer.
Basis for qualified opinion: In June 2025, former/current employees were sued for breach of trust/embezzlement; insufficient audit evidence obtained regarding impact of internal investigation on prepayments, short-term loans, inventory, etc.
Disclaimer on internal control: Unable to express an opinion on effectiveness due to the same incident.
Previous audit report dated March 15, 2024 is no longer valid and reissued.
FY2023 net loss of KRW 2.07 billion, accumulated deficit of KRW 3.01 billion, debt ratio 188.87%, net borrowing ratio 92.31%.
Treasury shares of 3,234,982 shares held (12.39%).
Ongoing litigation related to Pharmaceutical Affairs Act violation in first trial; appeal pending.